Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes  by Saldanha-Araujo, Felipe et al.
ava i l ab l e a t www.sc i enced i r ec t . com
www.e l sev i e r . com/ l oca te / sc r
Stem Cell Research (2011) 7, 66–74REGULAR ARTICLE
Mesenchymal stromal cells up-regulate CD39
and increase adenosine production to suppress
activated T-lymphocytes
Felipe Saldanha-Araujoa,⁎, Flávia I.S. Ferreirab, Patrícia V. Palmaa,
Amélia G. Araujoa, Regina H.C. Queirozb, Dimas T. Covas a,
Marco A. Zagoa, Rodrigo A. Panepucci aa National Institute of Science and Technology in Stem Cell and Cell Therapy (INCTC), Center for Cell Therapy (CTC),
Regional Blood Center and Faculty of Medicine of Ribeirão Preto— University of São Paulo (FMRP-USP), Ribeirão Preto, Brazil
b Department of Clinical, Toxicological and Bromatological Analysis, University of São Paulo, Ribeirão Preto, BrazilReceived 14 January 2011; received in revised form 12 March 2011; accepted 1 April 2011
Available online 8 April 2011Abstract Mesenchymal stromal cells (MSCs) suppress T cell responses through mechanisms not
completely understood. Adenosine is a strong immunosuppressant that acts mainly through its receptor A2a (ADORA2A).
Extracellular adenosine levels are a net result of its production (mediated by CD39 and CD73), and of its conversion into inosine by
Adenosine Deaminase (ADA). Here we investigated the involvement of ADO in the immunomodulation promoted by MSCs. Human T
lymphocytes were activated and cultured with or without MSCs. Compared to lymphocytes cultured without MSCs, co-cultured
lymphocytes were suppressed and expressed higher levels of ADORA2A and lower levels of ADA. In co-cultures, the percentage of
MSCs expressing CD39, and of T lymphocytes expressing CD73, increased significantly and adenosine levels were higher. Incubation
of MSCswithmedia conditioned by activated T lymphocytes induced the production of adenosine to levels similar to those observed
in co-cultures, indicating that adenosine production was mainly derived from MSCs. Finally, blocking ADORA2A signaling raised
lymphocyte proliferation significantly. Our results suggest that some of the immunomodulatory properties of MSCsmay, in part, be
mediated through the modulation of components related to adenosine signaling. These findings may open new avenues for the
development of new treatments for GVHD and other inflammatory diseases.
© 2011 Elsevier B.V. All rights reserved.Introduction
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doi:10.1016/j.scr.2011.04.001marrowmicroenvironment, suchasbone, adipose, and stromal
tissues (Friedenstein et al., 1966; Pittenger et al., 1999).
Another important propriety of MSCs is the immunosuppressive
effect they have on several immune cells, including B, T, and
Natural Killer (Corcione et al., 2006; Di Nicola et al., 2002;
Krampera et al., 2003; Rasmusson et al., 2005; Spaggiari et al.,
2006; Tse et al., 2003). One of the mechanisms by which MSCs
modulate immune responses is through generation of regula-
tory T-cells (Tregs) (Di et al., 2008; Maccario et al., 2005;
Prevosto et al., 2007). Recently, it was shown that Tregs.
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plays an important role in Tregs-mediated immunosup pression
(Borsellino et al., 2007; Deaglio et al., 2007; Kobie et al., 2006;
Mandapathil et al., 2010).
Adenosine is constitutively present at low levels in the
extracellular space, but its concentration increases in meta-
bolic stress (Sitkovsky and Lukashev, 2005). Adenosine has
various immunoregulatory activities that are mediated through
four adenosine receptor: A1, A2a, A2b, andA3 (Thiel et al., 2003).
It has been suggested that A2a adenosine receptors (ADORA2A)
act as “sensors” for extracellular adenosine levels (Sitkovsky
and Ohta, 2005). In immune cells, ADORA2A signaled by
adenosine induce an elevation of cytoplasmatic cAMP, a strong
immunosuppressive agent (Sitkovsky et al., 2004; Ohta and
Sitkovsky, 2001; Gessi et al., 2007; Fredholm et al., 2003) that
suppress T cell and cytokine secretion and ultimately prevents
inflammation (Lappas et al., 2010; Koshiba et al., 1997).
During inflammation, adenosine production is increased
and mediated by two sequential enzymes, CD39 and CD73.
CD39, a member of the ecto-nucleoside triphosphate dipho-
sphohydrolase family, converts ATP and ADP into 5′-AMP
whereas CD73, an ecto-5′-nucleotidase, converts 5′-AMP into
adenosine (Resta et al., 1998; Eltzschig et al., 2003; Behdad
et al., 2009). Adenosine levels are controlled by Adenosine
Deaminase (ADA) that coverts adenosine into inosine (Franco
et al., 1998). ADA can bind to CD26, which reduces the local
concentration of adenosine on the cell surface and prevents
the binding between adenosine with its receptors, mainly
ADORA2A. The lack of this signal allows T cells to escape from
the adenosine-mediated inhibition mechanism, leading to
inflammation (Morimoto and Schlossman, 1998; Kameoka
et al., 1993; Dong et al., 1996).
Although generation of adenosine by Tregs has been
reported (Borsellino et al., 2007; Deaglio et al., 2007; Kobie
et al., 2006; Mandapathil et al., 2010), the role of MSC in the
modulation of adenosine levels, in inflammatory situations,
such as those observed following T-lymphocyte activation, has
not been established. Herewe investigated the involvement of
components related to adenosine signaling in the immunomo-
dulation promoted by MSCs. Our results show that under
inflammatory stimuli, such as that provided by activated T-
lymphocytes, an increased percentage of MSCs express CD39,
resulting in an increased production of adenosine. Specific
blocking of adenosine signaling through ADORA2A receptors
resulted in increased T-lymphocyte proliferation, confirming
the immunosuppressive role of MSC-derived adenosine. We
also show that, in the presence of MSC, T-lymphocytes
(including Tregs) express CD73. These findings have important
implications in the understanding of the molecular mecha-
nisms underlying the immunomodulatory properties associat-
ed with MSCs. Finally, this knowledge may help in the
development of new protocols for the treatment of GVHD
and other inflammatory diseases.Figure 1 CD3+ lymphocyte proliferation assay. Representative
flow cytometry of BrdU incorporation by CD3+ lymphocytes.
CD3+ lymphocytes were activated by anti-CD2/CD3/CD28 beads
and cultured without (L) or with (L/M) MSCs. Evaluation was
performed on the fifth day following activation.Results
MSC characterization
Cultured MSCs derived from human bone marrow showed
capacity for differentiation into adipocytes, chondrocytes,
and osteocytes and a typical MSC immunophenotype wasobserved in the cultured samples. MSCs were positive for
CD73, CD90, CD29, CD13, CD44, CD49e and HLA-class I
markers and negative for hematopoietic cells markers (CD34,
CD14, CD45, and glycophorin A), endothelial cells (CD31 and
KDR), and HLA-class II (Supplemental Fig. 1).Suppression of T cell proliferation by MSCs
Proliferation of activated T cells was inhibited by MSCs. We
observed that only half of the cells co-cultured with MSCs
incorporated BrdU, as compared to cells cultured without
MSCs. For instance, while the percentage of proliferating
cells was 37.93% for T cells cultured without MSCs, only
18.43% of the cells cultured with MSC actively incorporated
BrdU (Fig. 1). This experiment was repeated three times and
similar results were found (data not shown).ADA and ADORA2A mRNA levels in CD4+ T cells
cultivated with or without MSCs
T cells cultured with MSCs had lower levels of ADA transcripts
(p=0.0460) (Fig. 2A) and higher levels of ADORA2A tran-
scripts (pb0.0001) (Fig. 2B), when compared to cultured
cells without MSCsADA activity quantification
Although not statistically significant, a higher ADA activity
was observed in the culture media obtained from T cells
cultivated with MSCs, as compared to that observed in
cultures without MSCs (Supplemental Fig. 2).Expression of CD26, CD39 and CD73 in CD4+ T cells,
in CD4+CD25hi Tregs, and in MSCs
Disregarding the presence of MSC in the culture, the
percentage of cells expressing CD26 was higher in Tregs
than in CD4+ T cells (Fig. 3A). Of notice, the percentage of
CD4+ T cells expressing CD26 was significantly lower when co-
cultured with MSCs than without (p=0.0016), while the
percentage of Tregs expressing CD26 was not changed.
Figure 2 ADA and ADORA2A mRNA levels. CD3+ T cells from 3 healthy volunteers were activated with anti-CD2/CD3/CD28 beads and
cultured without or with MSCs. On the fifth day following activation, CD4+ T cells were immunomagnetically purified from lymphocyte
only cells (CD4 L) and from lymphocyte plus MSCs (CD4 L/M), and real time PCR was performed. (A) ADA mRNA levels; (B) ADORA2A
mRNA levels. The relative fold values were obtained by the 2−ΔΔCt method using the median Ct value of the samples from cells
cultivated without MSCs, as a reference.
68 F. Saldanha-Araujo et al.We observed that the percentage of cells expressing CD39
was significantly higher in Tregs than CD4+ T cells. There was
no difference between activated T cells cultured with or
without MSCs (Fig. 3B).
A very small percentage (~1.5%) of T cells (both, CD4+ T
cells or Tregs) expressed CD73 in cultures carried in the
absence of MSC; nevertheless, when cultured in the presence
of MSC, a higher percentage of these cells expressed CD73.
Moreover, although not statistically significant, in MSC co-
cultures, the percentage of Tregs expressing CD73 was 31%
higher than the observed for CD4+ T cells (Fig. 3C). Of notice,
the percentage of double positive CD39+CD73+ Tregs raised
dramatically upon co-culture with MSCs (Fig. 3D).
Finally, the evaluation of CD39 and CD73 in MSC, cultured
alone or in the presence of activated T cells, revealed that
the percentage of MSCs expressing CD39 (Fig. 3E) was
significantly increased (p=0.0094) from 15% to approximate-
ly 35%. Almost all MSC express CD73 when cultured alone
and, in the presence of activated T cells, this percentage
remained above 90% (Fig. 3F). As a result, the percentage of
double positive CD39+CD73+ MSC was three times higher,
when co-cultured with activated lymphocytes, as compared
to MSC cultured alone (Fig. 3G).Adenosine quantification
Higher levels of adenosine were found in the supernatant of
MSC co-cultures than in the cultures without MSCs
(p=0.0009). In addition, we observed that in the presence
of supernatant of activated T cells, MSCs produced two times
more adenosine than the MSCs cultured without inflamma-
tory stimulus (Fig. 4).Adenosine signaling through ADORA2A is involved in
T-lymphocyte suppression by MSCs
As expected, proliferation of lymphocytes pre-treated with
ZM 241385 (a highly selective ADORA2A antagonist) and co-
cultured with MSCs, was significantly higher than similarlyco-cultured untreated T-lymphocytes with a mean of 29%
more proliferating cells, p=0.013 (Fig. 5).Discussion
Our study shows that in an inflammatory environment, such
as that provided by activated T-lymphocytes, MSCs elevate
CD39 expression and increase the production of adenosine,
suppressing T cell proliferation. In addition, suppressed T
cells present elevated levels of ADORA2A, that when
blocked, partially restores T-lymphocyte proliferation.
These results are in line with the known strong immuno-
suppressive effects of extracellular adenosine accumulation,
mediated mainly through ADORA2A adenosine receptors
(Sitkovsky and Ohta, 2005), and with previous reports
showing the role of adenosine production by Tregs in immune
response suppression (Deaglio et al., 2007; Kobie et al.,
2006; Mandapathil et al., 2010; Schmitt et al., 2009).
Moreover the cellular expression of ADORA2A in T cells is
directly proportional to the intensity of T cell response to
adenosine (Apasov et al., 2000; Armstrong et al., 2001),
inhibiting T cell activation and expansion (Huang et al.,
1997). Concordantly, our results show that in co-culture, the
presence of MSCs induced a higher expression of ADORA2A on
CD4+ T cells. Also, adenosine concentration and CD39
expression were significantly higher on MSCs cultured with
activated T cells.
Adenosine levels in co-cultures (mean of 72 ng/mL) are
partially resultant from the production mediated by Tregs,
nevertheless, at least more than half of the adenosine found in
co-cultures can be attributed to MSCs, as adenosine concen-
tration in the medium of MSCs cultured alone reached up to
43 ng/mL.Moreover,when themediumofMSCs cultured alone
was substituted by that of activated lymphocytes cultured
alone (in the 3rd day of culture), the concentration rose up to
91 ng/mL. Although it can be speculated that 5′-AMP
generated from ATP by CD39+ Tregs could serve as substrate
for the production of adenosine by CD73+ MSCs, our results
indicate that MSC plays a major role in the production of
adenosine in co-cultures.
Figure 3 CD26, CD39 and CD73 expression. CD3+ T cells from 3 healthy volunteers were activated with anti-CD2/CD3/CD28 beads
and cultured with or without MSCs. CD26, CD39 and CD73 expression was analyzed in CD4+ T cells and CD4CD25hi cells (Tregs) were
obtained from cultures without MSCs (CD4 L and Treg L) or with MSCs (CD4 L/M and Treg L/M). CD39 and CD73 were also analyzed in
MSC without (M) or with (M/L) activated lymphocytes. (A) CD26 expression in CD4+ T cells and Tregs cultured without or with MSCs. In
co-culture, CD26 expression in Tregs was 91.7±1.3%, whereas CD4+ T cells expressed 59.8±3.5% (p=0.0006). T cells cultivated without
MSCs showed 94.7±2.2% and 82.9±0.7% of CD26 expression in Tregs and CD4+ T cells, respectively (p=0.0036). In addition, expression
of CD26 was lower in CD4+ T cells from co-culture than from culture without MSCs (p=0.0016); (B) CD39 expression in CD4+ T cells and
Tregs cultured without or with MSCs. The expression of CD39 was significantly higher in Tregs than CD4+ T cells, either in activated
T cells cultured with (p=0.0027) and without (p=0.0001) MSCs; (C) CD73 expression in CD4+ T cells and Tregs cultured without or with
MSCs. CD4+ T cells from both cultures showed a higher expression of CD73 (11.8±2.3%) than CD4+ T cells cultivated without MSCs (1.2±
0.3%) (p=0.0057). In Tregs from co-culture, the CD73 expression was significantly higher than the corresponding cells from culture
without MSCs (17.0±4.0% against 1.2±0.1%) (p=0.0090); (D) percentage of CD39 and CD73 double positive CD4+ T cells and Tregs
cultured without or with MSCs; (E) CD39 expression in MSC without or with activated lymphocytes. MSCs presented a higher expression
of CD39 (34.9±5.0% against 15.5±0.4%) compared to MSCs cultured without T cells (p=0.0094); (F) CD73 expression in MSC without or
with activated lymphocytes. MSCs presented a lower expression of CD73 (91.1±2.4% against 99.3±0.2%) compared to MSCs cultured
without T cells (p=0.0142). (G) Percentage of CD39 and CD73 double positive MSC cultured without or with activated lymphocytes.
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of ADA on CD4+ T cells. Although not statistically significant,
ADA activity was higher in MSC co-cultures. It is possible that
a larger number of samples would reveal a significant
difference in ADA activity between cultures. The increased
ADA activity observed may be explained, at least in part, by
the lower percentage of CD4+ T cells expressing CD26, when
in the presence of MSCs. With lower levels of CD26 more ADA
molecules would be expected to be found free in the
supernatant.
Interestingly, even with higher ADA activity, adenosine
levels were higher in co-culture. Mandapathil et al.(2010)
revealed that low CD26 expression is a characteristic of
naturally-occurring Tregs, whereas CD4+ T cells have
elevated expression of this protein. Differently, we found
that the expression of CD26 was higher in Tregs than in CD4+
T cells, in both culture systems. This elevated CD26
expression in Tregs may constitute a protective mechanism
that increases ADA surface levels, preventing Tregs to be
affected by adenosine signaling (Dong et al., 1996).
Inversely, in CD4+ T cells co-cultured with MSC, the reduced
expression of CD26, and the consequent low levels of ADA on
the cell surface, would allow adenosine mediated suppres-
sion to occur.Recent data have shown that CD39 surface molecule is
expressed predominantly in CD4+CD25hi Tregs (Mandapathil
et al., 2010; Schmitt et al., 2009), suggesting that this ecto-
enzyme may be useful to define human Tregs subsets
(Borsellino et al., 2007; Dwyer et al., 2007; Schmitt et al.,
2009). Differently than CD4+CD25hi Tregs, this CD4+CD25hi
CD39+ subset is able to suppress pathogenic Th17 cells
(Fletcher et al., 2009). Consistent with other authors, in our
study, the CD39 was predominantly expressed in CD4+CD25hi
Tregs, both generated in the absence or in the presence of
MSC.
CD73 can be detected in different cell types and it is
possible that its physiological role differs according to the
cell context (Zimmermann, 1992). Besides the enzymatic
activity of CD73, its different functions include signal
activation in leukocytes (Robinson, 1991) and T cell adhesion
into endothelium (Airas et al., 1993). Recent data show that
the expression of CD73 is very low in T cells, and that this
protein is mainly localized in the cytosol of human naturally-
occurring Tregs (Alam et al., 2009). Differently, murines
present elevated CD73 expression on the surface of CD4+
T cells and CD4+CD25hi Tregs (Alam et al., 2009; Kobie et al.,
2006). In our study, CD4+ T cells and CD4+CD25hi Tregs
generated by T cell activation presented low CD73
Figure 4 Adenosine quantification. CD3+ T cells from 3 healthy
volunteers were activated with anti-CD2/CD3/CD28 beads and
culturedwithout (L) or with (L/M) MSCs. T cell culture supernatant
presented higher levels of adenosine (ADO) in the co-culture than
in the culture without MSCs (0.072±0.005 μg/mL against 0.006±
0.006 μg/mL; p=0.0009). In addition, MSC culture produced
0.043 μg/mL of adenosine,whereas in thepresence of supernatant
of activated T cells, the adenosine production was 0.091 μg/mL.
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shown). However, CD4+ T cells and CD4+CD25hi Tregs induced
by MSCs showed increased levels of CD73 expression on the
cell surface. These apparently conflicting results may be
explained by methodological differences used in each study
and the fact that CD73 stability on human cells surface is low
(Thomson et al., 1990; Airas et al., 1993).
During the revision of our manuscript, a paper coinciden-
tally reported that adenosine produced by murine MSCs
coexpressing CD39/CD73, mediates the inhibition of T cell
proliferation (Sattler et al., 2010). As shown by us, in their
report, they showed that MSCs coexpress the ectoenzymes
CD73 and CD39 and that they can generate adenosine, which
inhibits the proliferation of activated T lymphocytes,
through signaling mediated by the adenosine receptor
ADORA2A. Our work with human cells corroborates with
their independent findings (with mice cells). More impor-Figure 5 Inhibition of ADORA2A signaling. CD3+ T-cells were
activated with anti-CD2/CD3/CD28 beads and cultured alone (L)
or with MSCs (L/M). Alternatively, T-cells were pre-treated at
0.3 μM of the ADORA2A antagonist ZM 241385 (L/M ZM 241385). T-
lymphocyte treatment with ZM 241385 induced an increase in T-
cell proliferation by 29% compared to untreated T-lymphocytes
(p=0.013). Proliferation is shown relative to activated T-cells
cultured in the absence of MSCs. Results are themean (±SD) of two
independent experiments.tantly, our work adds further insights into the cross talk
between activated lymphocytes and MSCs (mediated by
inflammatory and immunomodulatory signals) leading to
increased percentages of double positive CD39+CD73+, both,
in MSCs and Treg lymphocytes.
Interestingly, activation of ADORA2A limits graft-versus-
host disease (GVHD) after allogenic hematopoietic stem cell
transplantation (Lappas et al., 2005). Our results indicate
that the modulation of components related to adenosine
signaling by MSCs, may be one of the mechanisms underlying
the claimed potential of this cells in the treatment of GVHD
(Le Blanc et al., 2008; Le Blanc et al., 2004). Our findings
may open new avenues for the development of new
treatments for GVHD and other inflammatory diseases.
Materials and methods
This study was approved by the Institutional Ethics Committee
and all samples were obtained after individual informed
consent was provided.
Isolation and characterization of MSCs
Approximately 10 mL of human bone marrow aspirates was
collected from healthy donors. Mononuclear cells were
separated by Histopaque®-1077 (Sigma, St. Louis, MO, USA).
MSCs isolated by plastic adherence as previously described
(Silva et al., 2003), and cultured at a concentration of 2–4×105
cells/mL in 25 cm2 flasks with alpha-MEM (Gibco-BRL, Gai-
thersburg,MD,USA) supplementedwith 15% fetal bovine serum
(FBS — HyClone, Logan, UT, USA), 2 mmol/l L-glutamine, and
100 U penicillin/streptomycin (Sigma, St. Louis, MO, USA).
Non-adherent T cells were removed after 72 h and the
formation of small colonies was observed 3 to 4 days later.
The plastic-adherent MSCs from the fourth passage were used
in the experiments.
Cultured MSCs were immunophenotypically characterized
using the following monoclonal antibodies: CD-33-FITC, CD45-
FITC, CD31-FITC, HLA-DR-FITC, Cadherin-5-FITC, Glycophorin-
FITC, CD73-PE, CD146-PE, CD90-PE, CD29-PE, CD44-PE, CD13-
PE, CD49e-PE, HLA-ABC-PE, CD34-PE, CD14-PE, CD54-PE,
CD166, and AC-133-PE (Pharmingen, San Jose, CA, USA).
Adipogenic, osteogenic, and chondrogenic MSC differentiation
potential were evaluated as previously described (Silva et al.,
2003). Basically, after incubation with the specific differen-
tiation medium, cells were fixed and stained by the von Kossa
method (calcium deposition, for osteocyte differentiation),
with Sudan II and Scarlet stains (lipid accumulation, for
adipocyte differentiation), or immunostained with anti-type II
collagen (for chondrocyte differentiation). The cells were
analyzed with Axioskop 2.0 Zeiss microscope equipped with an
Axiocam camera (Carl Zeiss, OberKochen, Germany).
Isolation of peripheral blood mononuclear cells and
immunomagnetic selection of T-cells
Peripheral blood mononuclear cells (PBMCs) were isolated from
the blood of healthy volunteers and separated using Ficoll-
Paque PLUS (Amersham Biosciences, Uppsala, Sweden). Next,
they were washed three times with PBS 1×. We used the Pan T
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according to the manufacturer's recommendations for the
immunomagnetic selection of CD3+ cells. Briefly, non-CD3+ T
cells were depleted from PBMCs using a mixture of antibodies
and secondary antibodies linked to magnetic microbeads, using
magnetic columns and VarioMACS magnet (Miltenyi Biotec).
Selected CD3+ T cells with purity above 95%, determined by flow
cytometry, were used in further experiments.
T-cell activation
Selected CD3+ T cells were activated using the T Cell
Activation/Expansion Kit, according to the manufacturer's
instructions (Miltenyi Biotech). In short, purified T cells,
resuspended in RPMI medium (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% FBS (HyClone), were briefly incu-
bated with anti-biotin magnetic particles, pre-loaded with
biotinylated antibodies against human CD2, CD3, and CD28
(in a ratio of 1 particle for 2 cells), mimicking activation by
antigen-presenting cells.
Immediately following activation, 2.5×105 activatedT cells
were culturedwith orwithout 5×104 MSCs, previously adhered
to the bottom of a 24 well plate in a total volume of 1 mL of
medium (RPMI, 10% FBS). After 3 days, 20 U/mL of human
recombinant IL-2 (Peprotech, Rocky Hill, NJ, USA) was added
to the cultures and evaluations were carried on the 5th day.
Proliferation assay
To evaluate the capacity of MSCs to modulate lymphocyte
proliferation, bromodeoxyuridine (BrdU) incorporation by
lymphocytes cultured in the presence or absence of MSCs was
analyzed, according to the manufacturer's instructions (BrdU
Flow Kit, BD Biosciences). In short, following activation,
5×105 CD3+ T-cells were cultured in the presence or absence
of 1×105 MSC, previously adhered to wells of a 12 well plate.
Following a period of 5 days, BrdU was added to wells,
cultured for 1 h and stained with PerCP-anti-CD3 and APC-
anti-BrdU monoclonal antibodies. FACsort flow cytometer
and CellQuest software (Becton-Dickinson, Mountain View,
CA, USA) were used to analyze fluorescent T cells.
Adenosine Deaminase activity
The relative ADA activity, in medium obtained from T cells
cultured either in the presence or absence of MSCs, was
measured using the Adenosine Deaminase Quimiada Kit (Ebram,
São Paulo, SP, Brazil), according to the manufacturer's in-
structions. This assay measures the enzymatic deamination of
adenosine into inosine (carried by ADA), indirectly, by
quantifying the variation in the absorbance derived from the
formation of colored quinone, resulting from a sequence of
reactions carried by enzymes present in the reaction buffer. In
brief, 50 μL ofmedium from cultureswas incubatedwith 110 μL
of Buffer A (Tris–HCl 50 mMpH 8, 4-AAP 0.2 mM, PNP 0.1 U/mL,
XOD 0.2 UI/mL, peroxidase 0.6 UI/mL, BSA 5%, and sodium
azide 0.01%) for 5 min and after the first absorbance measure-
ment, 55 μL of Buffer B was added (Tris–HCl 50 mM pH 4,
adenosine 10 mM and N-Ethyl-N-(2-hydroxy-3-sulfopropyl)- 3-
methylaniline, sodium salt, dehydrate 2 mM) and a final
absorbance measurement was done 8 min later. All sampleswere processed in parallel in a microplate spectrophotometer
Versamax system (Molecular Devices, Sunnyvale, CA, USA) and
the difference between the final and the first measured
absorbance was used as a relative measure of activity.
Real-time PCR
For gene expression analysis, CD4+ T cells were positively
selected using anti-CD4 linked magnetic beads (Miltenyi
Biotech) from CD3+ cells obtained from the fifth day of
culture, following activation with anti-CD2/CD3/CD28 beads.
To analyze the expression of ADA and ADORA2A, CD3+ T
cell from 3 healthy volunteers were activated with anti-CD2/
CD3/CD28 beads and following a 5 day period, CD4+ T cells
were immunomagnetically purified (purity above 95%) and
real-time PCR was performed. Total RNA from CD4+ cells was
obtained using TRIZOL reagent (Invitrogen) and reverse
transcribed to cDNA using the High Capacity cDNA Archive
Kit (Applied BioSystems, Foster City, CA), following the
manufacturer's instructions. Real-time PCR for ADA
(Hs01110945_m1) and ADORA2A (Hs00169123_m1) were
done (in duplicate) with TaqMan probes and MasterMix
(Applied BioSystems). To normalize sample loading, the
differences of threshold cycles (ΔCt) were derived by
subtracting the Ct value for the internal reference (mean
of GAPDH and β-actin) from the Ct values of the evaluated
genes. The relative fold value was obtained by the 2−ΔΔCt
method (Pfaffl et al., 2001) using the median Ct value of the
samples from cells cultivated without MSCs, as a reference.
The ΔΔCt was calculated by subtracting the reference ΔCt
from the ΔCt values of the samples. Expression of all samples
was measured in a single plate for each gene evaluated.
Flow cytometry
Magnetic isolated CD3+ T cells from three independent samples
wereactivated andculturedwithorwithoutMSCs (as described
above), and evaluated on the fifth day after activation by flow
cytometry, using monoclonal antibodies and corresponding
isotope controls (Becton-Dickinson), as described below.
T cells were evaluated for the expression of CD26, CD39 and
CD73 inCD4+CD25hi regulatory T cells (Treg) and inCD4+CD25− T
cells. For this, two tubeswere labeled independently with anti-
CD4-PC5, anti-CD25-APC and anti-CD26-FITC; or with anti-CD4-
PC5, anti-CD25-FITC, CD39-APC and anti-CD73-PE. Additional-
ly, T cells were characterized according to size and complexity.
The percentage of cells expressing CD39 and CD73 among
MSCs (as defined by a gate on CD45 negative cells), was
obtained through the use of anti-CD45-FITC, anti-CD39-APC
and anti-CD73-PE.
Determination of adenosine levels by high pressure
liquid chromatography (HPLC)
Adenosine levels were quantified by HPLC-UV, as previously
described (Valerio et al., 2009). The analysis was performed
on HPLC system consisting of a Shimadzu Model (Kyoto,
Japan) LC 10 AD pump, Shimadzu Model SPD-10A ultraviolet
detector and chromatopac C-R6A integrator (Shimadzu).
Chromatographic separation was achieved at room tempera-
ture on a LiChrospher 100 RP-18 column [size 125×4 mm,5 mm
72 F. Saldanha-Araujo et al.particle size (Merck, Damstadt, Germany)]. The mobile phase
consisted of 0.5% of acetonitrile, 5% of methanol, and 94.5% of
sodium acetate buffer 0.25 M, pH 6.3. HPLC-grade water from
Milli-Q system (Millipore, Bedford, MA, USA) was used. The
flow ratewas 1.0 mL min−1, and the ultraviolet detector set at
254 nm. An adenosine standard curve (0.32–4 mg·mL−1) was
constructed in pure culture medium. For this purpose, the
stock solution of adenosine at 4 mg·mL−1 was prepared in
methanol and stored at −20 °C, and further diluted in culture
medium to yield the concentrations described above.
A total of 2.5×105 activated T cells were cultivated with or
without 5×104 MSCs for 5 days. Also, 5×104 MSCs were
cultivated in the same conditions, without lymphocytes. On
the third day of culture, the supernatant of activated T cells
(inflammatory situation) cultured without MSCs was added
to wells containing MSCs. After 5 days, 500 μL of each culture
supernatant was added to tubes containing 1 mL of acetoni-
trile, and immediately vortexed by 1 min and centrifuged, to
extract proteins and to stabilize adenosine. Next, collected
supernatant was dried under air flow and the pellet was
resuspended in200 μL ofmobile phase (0.5% of acetonitrile, 5%
of methanol and 94.5% of sodium acetate buffer 0.25 M, pH
6.3). Finally, resuspended samples were vortexed for 20 s and
100 μL of each sample was used for chromatographic analysis.
Adenosine standards were used to confirm the retention time
and the required run-time. Adenosine was quantified compar-
ing the retention time with the standards. Under the
conditions used, the limit of detection was 10 ng/mL and the
limit of quantification was 20 ng/mL.
Specific inhibition of ADORA2A signaling
To confirm the immunosuppressive role of adenosine
signaling, through ADORA2A receptors, on lymphocytes co-
cultured with MSCs, a potent and highly selective ADORA2A
antagonist (ZM 241385, TOCRIS Bioscience) was used.
T-cells were labeled by incubating them in a PBS solution
containing 0.1% human albumin and CFSE at a concentration
of 2.5 μM (Molecular Probes/Invitrogen) for 10 min at 37 °C,
when labeling was stopped by adding cold RPMI containing
10% fetal calf serum. Labeled lymphocytes were then
activated and cultured with or without MSCs for 5 days (as
described). In parallel, T-lymphocytes were pre-treated with
0.3 μM of ZM 241385 for 30 min, washed with PBS and
resuspended in medium before being co-cultured with MSCs,
as described elsewhere (Mandapathil et al., 2010). Results
were obtained from two independent experiments.
Statistical analysis
Where appropriate statistical significance was determined
using one-tailed unpaired T-test, considering p≤0.05.
Supplementary materials related to this article can be
found online at doi:10.1016/j.scr.2011.04.001.Acknowledgments
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